HopeStage
Back to all studies
Active Not RecruitingNCT05434156

Safety and tolerability of ELE-101 in healthy adults and people with depression

About this titleRead the official source — NCT05434156
Medication studyAges 18–65United Kingdom
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
Liverpool and 1 more locationSee all locations and recruitment
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: October 27, 2022
Recruitment status
Active Not Recruiting
Enrollment listed in the registry
84
Sponsor
Eleusis Therapeutics
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
United Kingdom
Age range
From 18 Years to 65 Years
Official registry ID
NCT05434156
Official title
Show the full official title

A Phase I, Randomised, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Intravenous Doses of ELE-101 in Healthy Adult Participants (Part 1) and Part 2, Open-Label Study to Evaluate a Range of Pharmacodynamic Effects of a Single Intravenous Dose of ELE-101 in Patients With Major Depressive Disorder.

Recruitment & locations

Not recruiting

Liverpool · Manchester

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Eleusis Therapeutics.

Does this study involve medication?

Yes. The study involves medication, including ELE-101 and ELE-101 Placebo.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as active, but no longer recruiting.

Want to explore more studies?

Explore studies